CD274 and neoplasm: Among 55 patients with TNBC (enrolled irrespective of BRCA mutation or PD-L1 status), the RECIST ORR was 21% (90% CI: 12–33%), with a higher response rate among patients with BRCAmut than BRCAwt tumours (47% vs. 11%, respectively; median PFS 8.3 vs. 2.1 months, respectively) [49].